A Study of Ixekizumab in Chinese Participants With Psoriasis Vulgaris
NCT03073213
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
32
Enrollment
INDUSTRY
Sponsor class
Conditions
Psoriasis
Interventions
DRUG:
Ixekizumab
Sponsor
Eli Lilly and Company